The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis

• Published in: Molecular cancer Vol. 19; no. 1; pp. 44 - 12
• Main Authors: Chen, Mengnuo, Wong, Chun-Ming
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 28.02.2020; BioMed Central; BMC
• Subjects: Adenosine - analogs & derivatives; Adenosine - chemistry; Animals; Biomarkers, Tumor - genetics; Cancer therapies; Carcinogenesis; Cells; Deoxyribonucleic acid; Disease; DNA; DNA methylation; Epi-transcriptome; Epigenetic inheritance; Epigenetics; Gene expression; Gene Expression Regulation, Neoplastic; Genes; Hepatitis; Hepatocellular carcinoma; Histones; Humans; Infections; Liver; Liver cancer; Liver Neoplasms - genetics; Liver Neoplasms - pathology; Mammals; Messenger RNA; Methylation; Methyltransferases; Mutation; N6-methyladenosine; Proteins; Review; RNA epigenetics; RNA Processing, Post-Transcriptional; RNA, Neoplasm - chemistry; RNA, Neoplasm - genetics; United States > US; Hepatocellular carcinoma; N6-methyladenosine; RNA epigenetics; Epi-transcriptome
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/s12943-020-01172-y

Liver cancer is a common cancer worldwide. Although the etiological factors of liver carcinogenesis are well defined, the underlying molecular mechanisms remain largely elusive. Epigenetic deregulations, such as aberrant DNA methylation and histone modifications, play a critical role in liver carcinogenesis. Analogous to DNA and core histone proteins, reversible chemical modifications on mRNA have recently been recognized as important regulatory mechanisms to control gene expression. N6-methyladenosine (m6A) is the most prevalent internal mRNA modification in mammalian cells. m6A modification is important for controlling many cellular and biological processes. Deregulation of m6A modification has been recently implicated in human carcinogenesis, including liver cancer. In this review, we summarize the recent findings on m6A regulation and its biological impacts in normal and cancer cells. We will focus on the deregulation of m6A modification and m6A regulators in liver diseases and liver cancers. We will highlight the clinical relevance of m6A deregulation in liver cancer. We will also discuss the potential of exploiting m6A modification for cancer diagnosis and therapeutics.